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Abstract
in the recent years, particular attention was given to the research aimed at optimizing the use of 
tumour epigenetic markers. one of the best known epigenetic changes associated with the process 
of carcinogenesis is aberrant dnA methylation. the aim of the present research was to evaluate 
the methylation profile of genes potentially important in the diagnosis and/or prognosis of equine 
sarcoids, the most commonly detected skin tumours in Equidae. the methylation status of poten-
tial promoter sequences of nine genes: APC, CCND2, CDKN2B, DCC, RARβ, RASSF1, RASSF5, 
THBS1 and TRPM1, was determined using bisulfite sequencing polymerase chain reaction (BSP-
Cr). the results of this study did not reveal any changes in the level of dnA methylation in the 
analysed group of candidate genes between the tumour and healthy tissues. despite numerous 
reports describing the aberrant methylation of the promoters of the analysed genes in human can-
cers, the data obtained did not confirm the existence of such relationships in the examined tumour 
tissues, which excludes the possibility of using these genes for the diagnosis of the equine sarcoid.
Key words: equine sarcoids, horse, tumourigenesis, DNA methylation, BSPCR
Sarcoids are among the most commonly diagnosed skin tumours in Equidae 
species. It is widely accepted that bovine papillomavirus (BPV) types 1 and 2 
*Funding for this study was provided by the National Research Institute of Animal Production, 
Balice, Poland. Research Project No. 04-008.1.
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are recognised as aetiological factors of sarcoid disease (Chambers et al., 2003). 
Recent research also indicates a possible contribution of type 13 (BPV13) to the 
sarcoids pathogenesis (Lunardi et al., 2013). While sarcoids are not fatal, their nodu-
lar form contributes to mechanical damage, which may cause discomfort and im-
pede the use of affected horses, thus affecting a horse’s value and causing consider-
able economic losses for their owners. What is more, progression of the diseased 
tissue may result in ulceration, contribute to infection and, depending on the loca-
tion of lesions, cause permanent impairment of motor function (Broström, 1995). 
Today, histological examination of sarcoids is considered the most reliable 
diagnostic procedure. Despite the fact that immunohistochemical methods belong 
to the most commonly used methods in the cancer diagnosis, they are not fully 
effective, especially in case of differentiation between deep dermal or subcuti- 
cular equine sarcoids (ie, nodular sarcoids) and other spindle cell tumours in 
the dermis and subcutis such as peripheral nerve sheath tumours (Bogaert et al., 
2011; Epperson and Castleman, 2017). Moreover, they are time consuming and 
require the use of organic solvents, often harmful to human health. Therefore, 
new diagnostic strategies are being sought that enable rapid and accurate diag- 
nosis.
In the recent years, particular attention was given to the research aimed at optimiz-
ing the use of tumour epigenetic cancer markers. One of the best known epigenetic 
changes associated with the process of carcinogenesis is aberrant DNA methyla-
tion. Local hypermethylation of CpG islands critical to the neoplastic transforma-
tion process is mainly associated with the promoter regions of tumour suppressor 
genes (TSG). These are primarily genes of proteins involved in cell cycle regulation, 
apoptosis regulation, and DNA repair, but also other genes whose protein products 
contribute to processes such as differentiation, angiogenesis, detoxication, and drug 
resistance (Das and Singal, 2004). 
Determination of the epigenetic changes may serve as a tool to develop panels 
of genes, in which promoter methylation may be correlated with the incidence of 
a disease. By way of example, a study of Melnikov et al. (2014) allowed assembling 
a panel of methylation biomarkers (BRCA1, CCND2, CDKN1A, GSTP, MYF3, 
RPL15 and TRANCE), which could be used to diagnose squamous cell carcinoma 
(SCC), the second most frequent skin cancer in humans. Furthermore, hypermeth-
ylation of some TSG is associated with poorer prognosis in different cancer types. 
For example, hypermethylation of the THBS1 promoter region was detected in solid 
tumour brain metastases, such as melanoma or lung cancer (Gonzalez-Gomez et al., 
2004). 
Identification of changes that occur in DNA methylation can broaden our knowl-
edge about molecular changes occurring during sarcoid genesis as well as could be 
used as the basis for developing novel alternative diagnostic approaches and thera-
peutic approaches in sarcoid treatment. Therefore, the objective of the present study 
was to examine the methylation profile for a panel of nine genes (APC, CCND2, 
CDKN2B, DCC, RARβ, RASSF1, RASSF5, THBS1 and TRPM1) tested for epigenetic 
silencing, resulting from hypermethylation of cancer suppressor genes in different 
types of human tumours. The criterion for choosing the genes was the documented 
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contribution of the products of these genes to processes such as cell cycle regulation, 
DNA repair and proliferation as well as the earlier data linking them to two types of 
human skin cancers – melanoma, the most common malignant tumour of melano-
cytes and squamous cell carcinoma (SCC) in which virus from Papillomaviridae 
family, similar to horse sarcoids, play an important role as the possible aetiological 
factor (Spugnardi et al., 2003; Furuta et al., 2004; Hoon et al., 2004; Maruya et al., 
2004; Chen et al., 2007; Carvalho et al., 2008; Bonazzi et al., 2011; Lindner et al., 
2013; Melnikov et al., 2014).
material and methods
material
The study material was obtained from the Veterinary Clinic at the University of 
Bern, Switzerland. Six horses diagnosed with sarcoids were analysed. From each 
individual, two tissue samples were collected at different sites: tumour tissue (L) 
and the tumour-distant skin (D), sampled from the unaffected region of normal skin. 
DNA was isolated from tissue using a DNeasy Blood & Tissue kit (Qiagen, Germa-
ny), converted with sodium bisulfite using Epitec Bisulfite Conversion Kit (Qiagen) 
and amplified with EpiTect Whole Bisulfitome Kit (Qiagen), following the manufac-
turer’s instructions.
Bisulfite sequencing (BSPCR)
A panel of nine candidate genes (APC, CCND2, CDKN2B, RARβ, RASSF1, 
RASSF5, THBS1, TRPM1, DCC), examined for DNA methylation level in differ-
ent types of human cancer, was selected for the analyses. The potential promoter 
regions were identified with the MatInspector (Genomatix) program. Fragments of 
the selected regions were amplified with BSPCR primers designed in CpG island 
flanking regions using Methyl Primer Express® Software v1.0 (Applied Biosystems 
Software) (Table 1). HotStarTaq® polymerase (Qiagen) was used for the amplifica-
tion. The touchdown PCR cycling conditions were: 95°C for 15 min, followed by 
5 cycles at 97°C for 5 sec, 62 or 58°C for 2 min and 72°C for 45 sec, and further 
35 cycles at 97°C for 5 sec, 60 or 56°C for 2 min, 72°C for 45 sec and the final 
elongation at 72°C for 7 min. To purify BSPCR products from excess primers and 
deoxyribonucleotides, a combination of two enzymes: shrimp alkaline phosphatase 
(FastAP™ Thermosensitive Alkaline Phosphatase, SAP, Thermo Fisher Scientific, 
USA) and E. coli exonuclease I (Exo I, Thermo Fisher Scientific) was used. The 
sequencing was performed using BigDye® Terminator v3.1 Cycle Sequencing Kit 
(Thermo Fisher Scientific).
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Table 1. Primer sequences used for amplification of regions analysed with BSPCR technique
Locus Accession 
number
Number 
of analysed 
CpG site
Primer sequences
Size 
of PCR 
products
APC NM_001301314 24 f 5' TTTGTTAATTTGTTTGTTTTGTGG 3' 362 bp
r 5' AACCCAACAACACCTCCAT 3'
CCND2 NM_001309189 10 f 5' TGGGTAGGAGTGTTAGGATTAG 3' 379 bp
r 5' AACAATTAACTCTCCTCCCTCT 3'
CDKN2B XM_001496235 12 f 5' TTAGTGGGTGGGAGGAGT 3' 450 bp
r 5' AACCCAAACRCAAACTAAC 3'
RARβ XM_001494115 8 f 5' GGTTGTTTGTTTTTGTAGGG 3' 306 bp
r 5' ATACCCAAACAAACCCTACC 3'
RASSF1 XM_014731655 29 f 5' TTTGTGAGGTTGAGTTGAG 3' 352 bp
r 5' TCCTCCTAACTACAATAACCACTA 3'
RASSF5 XM_001491727 50 f 5' GTGGTTTTYGAATTGTTTTG 3' 445 bp
r 5' CCACTACTCATACTACTATCCACC 3'
THBS1 NM_001308952 37 f 5' TGAGAAGTTTTAGGGTTTTTG 3' 394 bp
r 5' CCCAAAAATCCCTTACCTATA 3'
TRPM1 XM_005602846 5 f 5' TTTGGTGGGTATAGGGTTAAG 3' 391 bp
r 5' AATCTCCTAAACTCACCTCACA 3'
DCC XM_014727646 6 f 5' TTAGGAAATAGTGGTTTGGTATTT 3' 365 bp
r 5' CAAAAAACTTCCAACAACTACA 3'
Analysis of BSPCR results
The obtained sequencing chromatograms were inspected using FinchTV v1.4.0 
software (Geospiza Inc.) to reject low quality reads. The program was also used 
for qualitative analysis of DNA methylation whereby the presence or absence of 
DNA methylation in DNA sequence was identified by determining the cytosine or 
thymidine in CpG sites. Following the analysis of chromatograms, the sequences 
were compared with the horse genome reference sequence and visualized by BISMA 
software (Rohde et al., 2010). To quantify the level of CpG sequence methylation, 
the Mquant method described by Leakey et al. (2008) was used.
Statistical significance of differences in the level of DNA methylation between 
lesional and tumour-distant skin sample groups was determined using Wilcoxon 
non-parametric test or parametric t-test after distribution evaluation using the Shap-
iro-Wilk normality test (R Development Core Team, 2011).
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results
The DNA methylation profile of 181 CpG sites located within potential regula-
tory regions of the nine candidate genes (APC, CCND2, CDKN2B, RARβ, RASSF1, 
RASSF5, THBS1, TRPM1, DCC) was analysed in DNA samples obtained from six 
sarcoids and six tumour-distant skin samples. The analysis of BSPCR sequencing 
results showed no significant differences in the level of CpG sequences methylation 
between the healthy and tumour tissues, in any of the gene fragments under analy-
sis (P>0.05) (Table 2). The results revealed high level of methylation (from 74.89 
to 94.52% per sample with a mean of 81.65%±16.69 SD within control (D) group 
and from 79.69 to 91.73% with a mean of 83.62%±11.62 SD within sarcoid (L) 
group) of sites in TRPM1 promoter region and low level of methylation (range from 
3.81–6.88%, mean of 6.18%±9.76 SD for RARβ region within control (D) group to 
15.57–20.83%, mean of 17.52%±10.88 SD for RASSF1 region within control (D) 
group) in the promoter regions of the other genes (Figure 1 and 2). Application of 
the Mquant method proved the same trend in DNA methylation for the analysed tu-
mour and skin samples as well as a similar DNA methylation percentage (differences 
between groups ranged from 0.30% to 14.83% and were statistically insignificant). 
Detailed results of the methylation analysis for all the gene fragments are provided 
in the Table 2.
Figure 1. A fragment of the chromatogram of the RARβ promoter region indicating the absence of 
differences in the CpG methylation pattern between the sarcoid and healthy tissue samples (A – tumour 
distant skin (5D), B – sarcoid (5L); black arrows indicate CpG sites where cytosine was converted by 
bisulfite)
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Figure 2. A fragment of the chromatogram of the TRPM1 promoter region indicating the absence of 
differences in the CpG methylation pattern between the sarcoid and healthy tissue samples (A – tumour 
distant skin (1D), B – sarcoid (1L); black arrows indicate CpG sites where cytosine was not converted 
by bisulfite)
discussion
Research to date has shown that changes in the normal function of some genes 
have a significant role in various pathological processes, including tumour progres-
sion. Aberrant APC (Adenomatous Polyposis Coli) gene promoter methylation is one 
of the epigenetic changes observed in colon (Agrawal et al., 2007), lung (Virmani 
et al., 2001; Esteller, 2005) and prostate cancers (Esteller, 2005). Similarly, aberrant 
methylation of CCND2 (Cyclin D2) gene involved in cell cycle regulation, differen-
tiation and neoplastic transformation, was found in numerous human cancers (Evron 
et al., 2001; Oshimo et al., 2003; Furuta et al., 2004; Melnikov et al., 2014). In turn, 
aberrant methylation of the promoter of the CDKN2B (Cyclin-Dependent Kinase 
Inhibitor 2B), apart from inactivation due to mutation, was observed in many haema-
tological cancers, in myelodysplastic syndrome (MDS) and in acute myeloid leukae-
mia (AML) (Christiansen et al., 2003; Boultwood and Wainscoat, 2007). The DCC 
(DCC Netrin 1 Receptor) gene is a tumour suppressor whose inactivation by DNA 
methylation is correlated with the incidence and poor prognosis of oral squamous 
cell carcinoma (Ogi et al., 2002). In the case of RARβ (Retinoic Acid Receptor, Beta) 
gene, the findings of Fendri et al. (2009) may indicate that methylation of this gene 
could be associated with the prevalence of highly differentiated tumours and the 
advanced stages of tumourigenesis. Genes of the RASSF (Ras Association (RalGDS/
AF-6) Domain Family) gene family, have been frequently described in the study of the 
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epigenetic inactivation of genes in human cancers. For example, hypermethylation of 
the RASSF1A promoter region, was correlated with tumour stage and poor prognosis 
(Lee et al., 2001; Maruyama et al., 2001; Chan et al., 2003) and RASSF5 gene aberrant 
methylation, was shown in kidney and lung, liver, and neuroblastoma tumour cell lines 
(Djos et al., 2012). The THBS1 (Thrombospondin 1) gene is the first identified natural 
inhibitor of angiogenesis. However, the mechanisms controlling the expression of this 
gene are not completely understood. One possible mechanism is DNA methylation, 
which has been confirmed in glioma studies (Li et al., 1999). The protein product of the 
TRPM1 (Transient Receptor Potential Cation Channel, Subfamily M, Member 1) gene 
is most likely involved in the regulation of melanocyte physiology. Expression of this 
protein is inversely correlated with melanoma aggressiveness and used as a prognostic 
marker for melanoma metastases (Guo et al., 2012).
The main focus of the present study was to determine differences in the meth-
ylation level of potential promoter regions of candidate genes, between the sarcoid 
tissue and the healthy (control) tissue. The differences in methylation were identified 
by determining, in bisulfite-converted DNA, the sites indicative of differential meth-
ylation. The analysis of the sequencing results revealed methylation of the potential 
promoter region of the TRPM1 gene as well as the absence of methylation for CpG 
sequences of the other gene fragments in both tissues. Despite the numerous reports 
describing the abnormal methylation of the promoters of the analysed genes in hu-
man tumours, the data obtained failed to confirm these differences in the biological 
material under study. It can be then speculated that the analysed genes probably play 
no significant role in equine sarcoid progression. The literature data concerning DNA 
methylation and its importance in response to the treatment of animal tumours is 
scarce. To date, the analysis of the methylation of gene promoter sequences in horse 
sarcoids has been performed by one research team (Altamura et al., 2012; Strazzullo 
et al., 2012). Their study concerning the analysis of the methylation of regulatory 
sequences of the FHIT (Fragile Histidine Triad) and MGMT (O-6-methylguanine-
DNA Methyltransferase) genes, which are often silenced by epigenetic processes in 
a large number of human tumours, also did not confirm considerable differences in 
the methylation level of this genes between the horse sarcoid tissue and the healthy 
control tissue. However, they found the decreased MGMT and FHIT expression in 
the sarcoid tissue which could suggest involvement of epigenetic mechanisms.
The results of this study did not reveal any changes in the level of DNA methyla-
tion in the analysed group of nine candidate genes between the tumour and tumour-
distant skin tissues. At the same time, at this stage of research, it is concluded that 
DNA methylation of the APC, CCND2, CDKN2B, RARβ, RASSF1, RASSF5, THBS1, 
TRPM1 and DCC genes is not a significant factor in the progression of equine sar-
coids. Future research is needed to more clearly evaluate the role of aberrant meth-
ylation in the genesis and progression of equine sarcoids.
ethics approval 
The sample collection for this study was approved by the Animal Experimenta-
tion Ethics Committee of the Canton of Berne, Switzerland (BE 30/11; 11 April 
2011). 
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